Table 3.
The association between NRP1 protein concentration and demographic and clinicopathological characteristics of patients
| Patient/tumor characteristics | NRP1 concentration (mean values ± standard error of mean, pg/mL) | P-value |
|---|---|---|
| Age (years) | ||
| <50 | 27.99±10.39 | 0.59 |
| ≥50 | 38.24±16.35 | |
| Body mass index (kg/m2) | ||
| 25–29 | 33.44±13.97 | 0.92 |
| >29 | 35.54±14.67 | |
| Menopause status | ||
| Post | 39.9±14.85 | 0.39 |
| Pre | 21.84±8.85 | |
| TNM stage | ||
| I | 15.71±7.77 | 0.39 |
| II | 20.50±11.52 | |
| III | 57.96±20.81 | |
| IV | 0 | |
| Histological grade | ||
| I | 0 | 0.78 |
| II | 31.62±13.13 | |
| III | 40.42±16.35 | |
| Mitotic rate | ||
| 1 | 28.90±14.54 | 0.49 |
| 2 | 27.89±14.43 | |
| 3 | 61.95±26.66 | |
| Tumor size (cm) | ||
| ≤2 | 21.61±14.8 | 0.607 |
| 2–5 | 46.02±17.02 | |
| ≥5 | 26.95±26.95 | |
| Lymph node involvement | ||
| Positive | 66.44±24.33 | 0.03 |
| Negative | 18.33±7.32 | |
| HER2 | ||
| Positive | 35.71±14.16 | 0.52 |
| Negative | 22.58±9.95 | |
| ER | ||
| Positive | 36.67±12.46 | 0.57 |
| Negative | 20.21±14.32 | |
| PR | ||
| Positive | 27.43±8.44 | 0.37 |
| Negative | 46.91±27.21 | |
| Breast cancer phenotype | ||
| Luminal A | 11.42±4.81 | 0.205 |
| Luminal B | 52.26±19.57 | |
| HER2 | 0 | |
| Triple negative | 0 |
Abbreviations: NRP1, neuropilin-1; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor.